Globus Medical, Inc.

NYSE:GMED

Medical - Devices

Healthcare
$70.53 -2.71%

-$2.10 today

Market cap
$9.34B
Beta
0.95
P/E (TTM)
17.4
EPS (TTM)
$4.33
52W Low $51.79High $101.40

Volume 1.43M

Average 1.45M

GMED Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Globus Medical, Inc.NYSE: GMED

Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026

Stock-based compensation declines year over year

Q2 FY2026 stock-based compensation of $13.38M fell 1.7% year over year, ahead of the -3.9% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 6.1% from the prior quarter. Over 3 fiscal years it compounded at +14.9% a year.

Context

  • Stock-based compensation amounted to 1.7% of revenue in FY2025, down 0.5 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -1.7% holds above the trailing-twelve-month pace of -3.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$13.38M+6.1% QoQ
Last fiscal yearDec 2025
$49.78M-8.1% YoY
LTMJun 2026
$48.96M-3.9% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-1.7%——
1 year-8.1%——
3-year CAGR+14.9%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
49.78M USD
Year-over-year change
-8.1%
4-year CAGR
+12.9%

Stock-Based Compensation vs competitors

How GMED compares with its peers on the latest reported figures

  • GMED's LTM Jun 2026 stock-based compensation of $48.96M is the 4th largest of the 10 companies compared; the peer median is $42.3M.
  • Its year-over-year change of -3.9% is the 8th highest of 10, against a peer median of +9.6%.
  • Stock-based compensation amounts to 1.6% of revenue for GMED, versus a peer median of 2.4%.
GMED Competitors Peer median
Stock-Based Compensation for GMED and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SYKStryker CorporationLTM Jun 2026$251M +9.6%+13.1%1.0%
ZBHZimmer Biomet Holdings, Inc.LTM Jun 2026$98.2M +13.7%-4.9%1.2%
ATECAlphatec Holdings, Inc.LTM Mar 2026$75.06M -4.1%+22.0%9.5%
GMEDGlobus Medical, Inc.LTM Jun 2026$48.96M -3.9%+14.9%1.6%
SNNSmith & Nephew plcFY2025$43M +7.5%+2.4%0.7%
OFIXOrthofix Medical Inc.LTM Mar 2026$42.3M +40.4%+15.9%5.1%
SIBNSI-BONE, Inc.LTM Mar 2026$24.89M -2.4%+3.4%12.1%
KIDSOrthoPediatrics Corp.LTM Mar 2026$17.9M +22.5%+38.6%7.4%
BVSBioventus Inc.LTM Mar 2026$13.52M +36.9%-10.3%2.3%
XTNTXtant Medical Holdings, Inc.LTM Mar 2026$2.88M -27.4%+5.5%2.4%
Peer median (excluding GMED) $42.3M+9.6%+5.5%2.4%

Competitors are the stored peer set for GMED. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income149.19M190.17M122.87M102.98M537.87M
Depreciation & Amortization69.87M68.25M144.73M254.02M276.84M
Deferred Income Tax(17.62M)(22.22M)(57.79M)(125.9M)18.63M
Stock-Based Compensation30.59M32.81M52.74M54.19M49.78M
Change in Working Capital(17.25M)(105.26M)(116.6M)(97.55M)(82.71M)
Accounts Receivables(25.9M)(50.84M)(49.91M)(78.06M)(52.18M)
Inventory(11.97M)(61.75M)(70.33M)(29.86M)(17.6M)
Accounts Payables3.68M14.42M(14.22M)17.66M8.49M
Other Working Capital16.93M(7.09M)17.87M(7.3M)(21.42M)
Other Non-Cash Items61.5M14.72M97.54M332.9M(46.96M)
Operating Cash Flow276.27M178.47M243.5M520.64M753.45M
Capital Expenditures(56.9M)(74.05M)(78.27M)(115.43M)(164.68M)
Acquisitions (Net)(34.49M)(31.44M)(296.03M)(17.64M)13.46M
Purchases of Investments(622.36M)(419.53M)(100.64M)(113.5M)(107.53M)
Sales of Investments337.81M414.65M777.91M70.52M179.49M
Other Investing Activities0000(275.75M)
Investing Cash Flow(375.94M)(110.36M)302.97M(176.05M)(355.01M)
Debt Repayment00000
Common Stock Issued00000
Common Stock Repurchased0(144.49M)(225.56M)(85.79M)(300.45M)
Dividends Paid00000
Other Financing Activities54.15M34.53M(6.26M)58.09M(378.71M)
Financing Cash Flow54.15M(109.96M)(231.82M)(27.7M)(679.16M)
Effect of Forex Changes(810K)(747K)2.18M255K22.45M
Net Change in Cash(46.33M)(42.6M)316.83M317.15M(258.28M)
Free Cash Flow219.38M104.42M165.23M405.21M588.77M

Globus Medical, Inc.

NYSE:GMED

Intrinsic Alpha fair value

Locked

Current Price

$70.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.